Table 2.

Laboratory data and incidence of CI-AKI (n (%) or median [IQR]) (n = 284)

	metformin n = 119	No Metformin n = 165	p value
HbA1c(%)	7.0 [3.6–14.2]	7.8 [6.9–8.8]	0.194
Hb(g/l)	141 [126–152]	120 [110–140]	0.079
cTnI peak (ng/ml)	7.0 [3.6–14.2]	7.8 [6.9–8.8]	0.842
Creatinine
Baseline (μmol/l)	76 [66–86]	73 [61–84]	0.105
Post PCI (μmol/l)	83 [72–98]	76 [64–76]	0.012
Relative creatinine change	11% [6–20%]	11% [5–22%]	0.858
post PCI (%)
≥ 50% increase	5 (4.2%)	9 (5.5%)	0.630
Absolute creatinine change	7.9 [2.4–13.2]	6.7 [0.2–12.7]	0.198
post PCI (%) (μmol/l)
≥ 27 μmol/l(0.3 mg/dl)	15 (12.6%)	15 (9.1%)	0.342
eGFR (ml/min/1.73m2)
Baseline (ml/min/1.73m2)	89 [73–104]	94 [72–113]	0.170
eGFR≤60 ml/min/1.73m2	9 (7.6%)	21 (12.7%)	0.163
Post PCI (ml/min/1.73m2)	77 [65–95]	87 [67–102]	0.092
Relative eGFR change	13.4% [6.4–25.1%]	13.5% [5.2–24.3%]	0.449
post PCI (%)
Absolute eGFR change	−7 [−16; 3]	−6 [−18; 3]	0.981
post PCI (ml/min/1.73m2)
CI-AKI	15 (12.6%)	17 (10.3%)	0.545

HbA1c glycosylated hemoglobin, Hb hemoglobin, eGFR glycosylated hemoglobin estimated glomerular filtration rate, cTnI cardiac troponin I, PCI percutaneous coronary intervention, CI-AKI contrast induced-acute renal injury